Richard Waldron
Director of Finance/CFO at BIOATLA, INC.
Net worth: 519 577 $ as of 2024-04-29
Active connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Jay Short | M | 66 |
Himalaya Therapeutics
 Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | 17 years |
| Carolyn Anderson Short | F | 59 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | 17 years |
| Scott Smith | M | 61 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | 6 years |
| Lawrence Steinman | M | 76 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | 8 years |
| Mary Gray | M | 71 | 4 years | |
| Susan Moran | M | 54 | 4 years | |
| Christian Vasquez | M | 48 | 9 years | |
| Sylvia Mcbrinn | F | 71 | 3 years | |
| Edward Williams | M | 68 | 3 years | |
| Mike Melnick | M | - | - | |
| Xiang Dong Tan | M | 69 |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
| Cathy Chang | M | - | - | |
| Eric Sievers | M | 60 | 5 years | |
| Susie Melody | F | - | - | |
| William J. Boyle | M | - | 11 years | |
| Gerhard Frey | M | - | 17 years | |
| Brian Zhang | M | - |
Himalaya Therapeutics
Himalaya Therapeutics Medical/Nursing ServicesHealth Services Himalaya Therapeutics is a Caymanian clinical-stage biotechnology company that is advancing its pipeline of novel monoclonal antibody and other protein therapeutic product candidates through clinical trials. The company is based in George Town, Cayman Islands, with operations in Taiwan and China. The company's product candidates have been developed using cab technology, which is protected by more than 500 issued and pending patents. Himalaya has two cab programs currently in phase 2 clinical testing in Taiwan\: BA3011, a novel conditionally active AXL-targeted antibody-drug conjugate (CAB-AXL-ADC), and BA3021, a novel conditionally active ROR2-targeted antibody-drug conjugate (CAB-ROR2-ADC). Himalaya has a co-development and collaboration agreement for an investigational CAB CTLA-4 antibody, BA3071, with BeiGene Ltd. for its development, manufacturing, and commercialization in Greater China. The company was founded by Carolyn Anderson Short and Jay M. Short, and the CEO is Brian Zhang. | - |
Connections Chart
Multi-company connection
Former connections
| Name | Gender | Age | Linked companies | Collaboration |
|---|---|---|---|---|
| Ira D. Lawrence | M | 71 | 8 years | |
| Donald R. Sellers | M | - | 8 years | |
| Friedhelm Blobel | M | 75 | 11 years | |
| Priyanka Belawat | M | 45 | - | |
| Richard Hawkins | M | 75 | 13 years | |
| Philippe Martin | M | - | 5 years | |
| Guy Levy | M | 42 | 2 years | |
| Andrew Witty | M | 59 |
Genelabs Technologies, Inc.
 Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | - |
| Craig A. Halverson | M | - | - | |
| Neil Gibson | M | 67 | 1 years | |
| Darryl Webster | M | 64 | - | |
| Chris Wagner | M | - |
Rauscher Pierce Refsnes, Inc.
| 3 years |
| Grace E. Colón | M | 57 | 2 years | |
| Mark Kubik | M | - | - | |
| Terry Gaines | M | - |
Rauscher Pierce Refsnes, Inc.
| 4 years |
| Todd Holder | M | - |
Rauscher Pierce Refsnes, Inc.
| 6 years |
| Joseph James Fitzsimmons | M | 75 |
Rauscher Pierce Refsnes, Inc.
| 1 years |
| Eduardo Bruno Martins | M | 61 | 8 years | |
| Eric J. Hoechstetter | M | - | - | |
| Khursheed Anwer | M | 64 |
gMed., Inc.
 gMed., Inc. BiotechnologyHealth Technology gMed is engaged in providing physicians with information solutions to “Care Better” for their patients and practice. The company provides Digital Charting solutions for Gastroenterology and Cardiology designed to eliminate paper, increase revenues, decrease costs and enhance patient care at the medical office, ambulatory surgery center and hosptial. gMED was founded in 1997 and is located in Weston, FL. | 6 years |
| Robert E. Phaneuf | M | 77 |
Rauscher Pierce Refsnes, Inc.
| 5 years |
| Israel Rios | M | 77 | 7 years | |
| Hans P. Schmid | M | 72 | 10 years | |
| Thomas Lee Cunningham | M | 81 |
Rauscher Pierce Refsnes, Inc.
| 3 years |
| Eivind Olsen | M | - |
Rauscher Pierce Refsnes, Inc.
| 1 years |
| Dana Baker | M | 60 |
Rauscher Pierce Refsnes, Inc.
| 2 years |
| Alfred R. Rudolph | M | 76 | - | |
| Heather Criss Keller | F | 58 |
Genelabs Technologies, Inc.
Genelabs Technologies, Inc. Pharmaceuticals: MajorHealth Technology Genelabs Technologies, Inc. discovery and development of pharmaceutical products to improve human health. The company was founded by Brian D. Frenzel and Frank C. Kung in 1983 and is headquartered in Redwood, CA. | - |
| Yong Ben | M | 50 | 2 years |
Statistics
| Country | Connections | % of total |
|---|---|---|
| United States | 44 | 95.65% |
| Cayman Islands | 6 | 13.04% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Richard Waldron
- Personal Network
